To provide an updated overview on the management of antiplatelet therapy in patients with coronary stents undergoing cardiac and noncardiac surgery.
INTRODUCTION
In patients with coronary artery disease (CAD), the use of antiplatelet therapy is key for secondary prevention of ischemic events [1] [2] [3] . Importantly, the number of percutaneous coronary interventions (PCI), which implies the use of dual antiplatelet therapy (DAPT), has increased worldwide in the last decades, and in the vast majority of cases a coronary stent is implanted [4, 5] . Among patients with stents, approximately 5-20% are estimated to undergo a surgical procedure within 2 years from PCI [6] [7] [8] [9] [10] . The largest study cohort published so far reported a rate of noncardiac surgery of 22.5% in the 24 months following PCI, with more than a half of surgical procedures occurring in the first year [11 && ]. Surgery was more frequent in patients with bare metal stent (BMS) compared with patients with drug-eluting stent (DES), but 11.8% of patients with BMS underwent early surgery (<6 weeks after stenting) compared with 46.7% of patients with DES (<12 months) [12] . Importantly, surgery has been identified as one of the main causes of early DAPT discontinuation after DES implantation [13] . In this scenario, finding the right balance between the thrombotic risk of DAPT interruption and the hemorrhagic risk of having a surgical procedure while on antiplatelet therapy is challenging, and no established management strategy has been well defined [14] [15] [16] [17] 18 && ,19
ISCHEMIC AND BLEEDING RISK OF ANTIPLATELET THERAPY IN PATIENTS REQUIRING SURGERY
DAPT with a combination of aspirin and one of the ADP P2Y 12 receptor inhibitors (clopidogrel, prasugrel, and ticagrelor) is currently recommended for at least 4 weeks in patients undergoing elective PCI with BMS, for 6-12 months in patients receiving DES (variable according to European and North American guidelines), and for 12 months in patients with acute coronary syndrome (ACS), irrespective of the management strategy (invasive or conservative) [1, 3, 20, 21] . Although the thrombotic risk is highest during the first month after stent implantation and still high within the first 6 months [22, 23] , a safe time period for antiplatelet therapy discontinuation has not been defined yet. This is indeed key in the management of DAPT in patients undergoing surgery, in order to balance thrombotic and hemorrhagic risk.
Surgery-related thrombotic risk
The thrombotic risk in CAD patients undergoing surgical procedures is made up of a combination of antiplatelet therapy interruption associated with the increased prothrombotic and inflammatory state that characterizes surgery (higher platelet count and adhesiveness, increased cytokine levels, release of neuroendocrine inflammatory mediators, and decreased or impaired fibrinolysis) [24] [25] [26] . Several studies have shown a high rate of ischemic events when surgery is performed after stent implantation, with timing between PCI and surgery playing a central role [27] [28] [29] [30] . The risk of BMS thrombosis is higher within 2 weeks after stent placement and lower after 4 weeks, which is approximately the time needed for BMS reendothelialization. DES thrombosis may occur later, even years after stenting, especially with first-generation DES, leading to a longer high-risk period [31,32 & ,33] . In a large cohort of patients (n ¼ 8116) who underwent major elective noncardiac surgery within 10 years after stenting, the incidence of 30-day ischemic events in patients with BMS was higher when the interval between stenting and surgery was less than 45 days (6.7%) compared with surgery performed between 45 and 180 days (2.6%) [34] . In patients with DES, the incidence of adverse events was 20% for surgical procedures performed within 45 days and 1.2% when the interval between stenting and surgery was longer than 180 days. Importantly, when surgery was performed 45 days after BMS and 180 days after DES, the thrombotic risk was very similar to that of intermediate-risk nonrevascularized patients [34] . The incidence of perioperative events seems, therefore, to decrease over time, with the first week after stenting considered the most critical [5] . In the Evaluation of Drug-Eluting Stents and Ischemic Events registry [6] , the risk of cardiac events was increased 27-fold in the week following noncardiac surgery in comparison with any other week after DES implantation.
Overall, these findings support the concept that after stent placement early surgery and antiplatelet therapy discontinuation are risk factors for cardiac events in the perioperative period. A three-fold increased risk of ischemic events has been shown in the case of aspirin discontinuation/noncompliance, with consistent effects in patients treated for ACS, primary prevention of CAD or post-coronary artery bypass grafting (CABG), and an even enhanced risk in patients treated with DES [35] . However, recent data suggested no association between antiplatelet cessation and adverse ischemic events after surgery and a limited impact of stent type [11 && ]. After both BMS and DES placements, the risk was stable at 6 months and the three factors most strongly associated with events were nonelective surgery, recent myocardial infarction (MI), and high cardiovascular risk [11 && ]. Similarly, the Cleveland Clinic series showed that the strongest independent predictor of 30-day postoperative ischemic
KEY POINTS
Surgical procedures are frequent in patients with coronary stents and carry an increased risk of hemorrhagic and thrombotic complications.
Management of antiplatelet therapy in the perioperative period is pivotal because it may strongly influence outcomes.
In the absence of well-defined recommendations from clinical practice guidelines, the management of antiplatelet therapy should be on the basis of patientspecific ischemic and bleeding risks, and on surgeryspecific bleeding risk.
If surgery cannot be postponed, aspirin should be continued throughout the perioperative period and decisions about DAPT should be on the basis of the thrombotic/hemorrhagic risk balance.
The use of bridging strategies with intravenous antithrombotic agents seems appealing in certain patient subsets, but is currently not routinely recommended.
events in patients with DES was MI in the 30 days before surgery, which led to a six-fold increased risk [36] .
Hemorrhagic risk vs. protective effect of perioperative antiplatelet therapy
Perioperative bleeding derive from the risk driven by the use of antithrombotic therapy combined with the hemorrhagic risk carried by the surgical procedure itself. Different surgical procedures are associated with different hemorrhagic risk, and certain procedures are usually not associated with postoperative bleeding unless performed in patients receiving antithrombotic medications in the perioperative period [37 & ,38 && ]. Cardiac surgeries, including CABG, are different from other major surgeries as they are characterized by altered fibrinolysis, platelet dysfunction from the pump and full heparinization therapy, which represent specific risk factors for bleeding [39] . Moreover, CABG is often performed in proximity of an ACS and in patients requiring DAPT.
Most of the studies of aspirin use in the preoperative setting are not randomized. Two underpowered clinical trials comparing low-dose aspirin vs. placebo in patients undergoing noncardiac surgery showed no significant differences in bleeding events within 30 days from surgery, and a potential risk reduction in postoperative major adverse cardiac events [40, 41] . A meta-analysis of 50 000 patients undergoing noncardiac surgery showed a 1.5-fold increased risk of bleeding with aspirin use, but no increase in the severity of bleeding, with the exception of transurethral prostatectomy and intracranial surgery [42] . Recently, in the Perioperative Ischemic Evaluation 2 (POISE-2) trial, patients (n ¼ 10 010) undergoing noncardiac surgery and at risk for vascular complications were randomized to receive either aspirin (100 mg/day) or placebo for 30 days during the perioperative period. The primary outcome (a composite of death or nonfatal MI at 30 days) was similar between groups (7.0% with aspirin vs. 7.1% with placebo; P ¼ 0.92), but adjunctive aspirin therapy led to a 23% relative increase in major bleeding events (4.6 vs. 3.8%; P ¼ 0.04). Results were consistent irrespective of aspirin use before the study. However, only approximately 5% of patients enrolled in the trial had previously been treated with coronary stents, making these results not generalizable to most patients who had undergone PCI [43 & ]. In the setting of CABG, aspirin has been shown to increase postoperative bleeding, which may be avoided using a dose lower than 325 mg [44] . However, the importance of aspirin therapy for graft patency in the year following CABG should also be noted [45, 46] . Further, aspirin use in the 5-7 days prior to CABG surgery is associated with a reduction of adverse ischemic events in the postoperative period [47, 48] .
Data on the perioperative use of P2Y 12 receptor inhibitors are scarce and mostly in patients undergoing CABG. The few available studies referring to noncardiac surgery indicate overall an increase in bleeding, strongly dependent on the hemorrhagic risk of the surgical procedure itself [38 && ]. Observational studies suggest an increase in postoperative chest tube drainage, transfusions, reoperation rates, hospitalization stay, and mortality when DAPT is maintained during CABG, with an important reduction when DAPT is discontinued for at least 5 days [37 & ,49-51] . In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, patients undergoing CABG after being exposed to clopidogrel (in addition to aspirin) had a nonsignificant reduction in ischemic events associated with a nonsignificant increase in major bleeding. However, the bleeding risk was strongly dependent on whether clopidogrel was stopped 5 days or less before surgery or more than 5 days, with a 53% increase in bleeding when clopidogrel was continued within 5 days before surgery [51] . The effect of clopidogrel on the excess of bleeding is independent of on-pump vs. off-pump surgery, but is influenced by the loading dose (300 vs. 600 mg) [52, 53] . Although results of meta-analysis showed higher rates of hemorrhagic complications associated with pre-CABG clopidogrel exposure, they yielded mixed results in terms of ischemic protection [49, 50] . Mortality seemed to be increased in patients with recent clopidogrel use, but this was mainly influenced by ACS status and urgency, which are markers of higher baseline patients' risk [54, 55] .
Few data are available for patients treated with the novel P2Y 12 receptor inhibitors prasugrel and ticagrelor. In the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) trial, a total of 368 (2.7%) ACS patients received at least one dose of study medication and afterward underwent CABG surgery. Despite an increase in the rate of TIMI major bleeding, platelet transfusion and mean 12-h chest tube blood loss, prasugrel was associated with a lower rate of death after CABG compared with clopidogrel (2.3 vs. 8.7%; P ¼ 0.025) [56] . The difference in bleeding was consistent whether prasugrel was administered 3 days or less before surgery or between 3 and 7 days [56] . These findings led to the recommendation that prasugrel should be discontinued at least 7 days before any surgery, including CABG [57, 58] . Ticagrelor, differently from clopidogrel and prasugrel, reversibly binds to the P2Y 12 receptor and is characterized by a faster offset of platelet inhibitory effect [59] . In the Platelet Inhibition and Patient Outcomes (PLATO) trial, 1899 patients (10.2% of study population) underwent CABG at any time after randomization. Compared with clopidogrel, ticagrelor did not increase the rate of TIMI CABG-related major and minor bleeding, with consistent findings using all other bleeding definitions, and including fatal CABG-related bleeding [60] . Importantly, ticagrelor use was associated with a lower rate of post-CABG mortality due to cardiovascular, bleeding, and infection complications [61] . Regulating authorities recommend discontinuing ticagrelor 5-7 days before surgery, if possible [62, 63] . The benefit on ischemic events with prasugrel and ticagrelor was more evident in the first 30 days after surgery, leading to the hypothesis that platelet P2Y 12 inhibition has an overall benefit in patients undergoing CABG, although at the expense of an increase in bleeding and transfusions.
PRACTICAL RECOMMENDATIONS
Overall, there is a lack of well-designed randomized clinical trials assessing the perioperative management of antiplatelet therapy in patients with coronary stents. Several recommendations have been provided but are mostly based on expert consensus and are characterized by low levels of evidence [14-17,18 && ]. Clinicians' decisions should, therefore, be based on the balance between the thrombotic and hemorrhagic risks that individually characterize each patient and each surgical procedure. (Fig. 1) . The four major clinical issues that need to be faced in the management of perioperative antiplatelet therapy are as follows: first, timing of surgery; second, interruption of antiplatelet therapy; third, resumption of antiplatelet therapy; and fourth, bridging therapy. Guidelines recommendations on these topics from the major cardiology societies are summarized in Table 1 .
Timing of surgery
The correct timing of surgery is strongly dependent on the clinical indication to antiplatelet therapy. First, unnecessary coronary stent placement should be avoided before surgery, as it has been shown that a systematic prophylactic coronary revascularization strategy before noncardiac surgery does not carry any clinical benefit in patients with stable CAD [64, 65] . This may not be possible in patients with severe ischemia or ACS and, if PCI is required, a careful balance between the urgency of noncardiac surgery and the risk of bleeding needs to be considered. In both stable and ACS patients, if the elective noncardiac surgery can be postponed at least 12 months, PCI with DES and prolonged DAPT may be considered. If the noncardiac surgery cannot be postponed and is likely to be performed within 1-12 months, placement of a BMS and 4-6 weeks of DAPT is considered safe [14] [15] [16] . In case of active cardiac conditions, it is reasonable to wait 4-6 weeks before performing elective surgery and PCI with balloon angioplasty only may be an option, if the angiographic result is good [14] [15] [16] . In this latter scenario, surgery cannot be postponed more than 6-8 weeks in order to avoid restenosis due to vessel recoil [66] . Indeed, these recommendations do not take into account emerging data suggesting a better safety profile of new-generation DES compared with first-generation DES and BMS, with lower rate of stent thrombosis and no need for prolonged DAPT [67] . Recent findings from randomized clinical trials suggest that a shorter DAPT (3-6 months in patients with ACS and 3 months in patients with stable CAD) is at least as safe and effective as prolonged DAPT, when new-generation zotarolimuseluting or everolimus-eluting DES are implanted [68] [69] [70] [71] . Accordingly, the Patterns of Nonadherence to Antiplatelet Regimens in Stented Patients (PARIS) registry recently showed that, in the setting of new-generation stents, the risk following DAPT cessation is very heterogeneous and is based on patients' risk profile as well as mode and timing of cessation. Further, it showed that, when recommended by physicians, brief interruption of DAPT for surgical procedures (both antiplatelet agents in 70% of cases) is safe. The overall contribution of DAPT cessation to cardiac risk is small, attenuates over time, with the highest risk in the first 7 days after cessation and no increased risk after 30 days, and is significantly increased only when both antiplatelet drugs are withdrawn [72 && ]. However, in all these studies, the overall event rate was very low. Even if this is in line with the event rates currently reported in the modern clinical trials [73] , these studies may have been underpowered to define a true signal on outcomes.
Interruption of antiplatelet therapy
Aspirin should be continued in the perioperative period, unless in high-bleeding risk surgeries, such as in spinal, intracranial, extra-ocular, urologic, or major reconstructive surgeries [14] [15] [16] . Aspirin interruption 3-5 days before CABG may also be considered in patients who refuse blood transfusions [18 && ]. The decision of stopping the P2Y 12 receptor inhibitors should be based on clinical judgment. If surgery is needed within 6 weeks from BMS implantation or within 6 months from DES, DAPT should be maintained if possible [14] [15] [16] . Recently, a consensus document endorsed by the Italian societies of cardiology, surgery, and anesthesiology provide specific recommendations on perioperative management of antiplatelet therapy on the basis of a comprehensive classification of the surgery-related hemorrhagic risk [38 && ]. If the hemorrhagic risk overcomes the ischemic risk, brief interruption of the P2Y 12 receptor inhibitor may be considered [14-16,38 && ]. Clopidogrel and ticagrelor should be stopped 5-7 days before surgery, whereas prasugrel should be stopped 7-10 days before [14-17,18 && ]. In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 h in order to reduce major bleeding [17] . When deciding to stop or maintain antiplatelet therapy, also the type of anesthesia technique should be taken into account: loco-regional anesthesia, in particular neuraxial techniques, may be affected by antiplatelet therapy, which leads to an increased risk of bleeding-related complications. While a safe neuraxial technique can be performed in patients on aspirin therapy, DAPT use during the week preceding a surgical intervention is a contraindication to any form of regional anesthesia, and a general anesthesia is recommended [74] . Given the variability in 
No statement
No statement CABG surgery ACCP [14] No statement In patients who are receiving ASA and require CABG, continue ASA around the time of surgery instead of stopping ASA 7-10 days before surgery. In patients who are receiving DAPT and require CABG, we suggest continuing ASA around the time of surgery and stopping clopidogrel/prasugrel 5 days before surgery instead of continuing DAPT around surgery.
Within 24 h after surgery
No statement AHA/ACC [17] No statement ASA should be administered preoperatively. For elective CABG, clopidogrel and ticagrelor should be discontinued for at least 5 days and prasugrel for at least 7 days. For urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 h to reduce major bleeding complications.
If aspirin was not initiated preoperatively, it should be initiated within 6 h postoperatively.
No statement individual response to antiplatelet therapy, platelet function testing may theoretically be a useful tool to tailor DAPT discontinuation before surgery, in order to minimize bleeding, waiting time, and thrombotic risk [75] . In the Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) study, the use of thromboelastography platelet-mapping assay in patients on antiplatelet therapy waiting for CABG surgery resulted in an approximately 50% shortening of the waiting period for clopidogrel-treated patients and was associated with the same amount of bleeding observed in clopidogrel-naïve patients [76] . Accordingly, the Society of Thoracic Surgeons guidelines state that in patients on DAPT undergoing cardiac surgery, it is reasonable to make decisions about surgical delay based on platelet function testing [77] .
Resuming antiplatelet therapy
If discontinuation in the perioperative period is required, antiplatelet therapy should be resumed as soon as possible after the surgical procedure, and possibly within 24 h. The P2Y 12 receptor inhibitor should be restarted with a loading dose [14-16,38 && ]. For patients undergoing CABG, aspirin should be restarted within the first 24 h (preferably within 6 h) and, if DAPT is still needed (patients within 1 year of ACS or with stents in nongrafted coronaries), clopidogrel should be restarted as soon as bleeding is controlled [14,17,18 && ]. The reason why antiplatelet therapy should be restarted as soon as possible is that thrombotic events are more likely to occur in the postoperative period, rather than in the preoperative, because of the surgical variables (i.e., enhanced prothrombotic state, bleeding, anesthesia), which add to the withdrawal of protection by antiplatelet therapy [30,37 & ].
Bridging therapy
In case of P2Y 12 inhibitor discontinuation, the routine use of parenteral antithrombotic therapy is not advised, as little evidence is available on the efficacy and safety of this strategy [14-17,18
Indeed, a bridging strategy seems appealing in order to minimize bleeding risk without a trade-off in ischemic protection in patients at high thrombotic risk who require DAPT discontinuation. If bridging is needed, antiplatelet agents should be preferred over anticoagulants, as arterial thrombosis is primarily driven by platelet adhesion and aggregation at the site of vascular injury [78] . Notably, unfractionated heparin has a prothrombotic effect and may potentially be harmful [79] . Although 
Low dose aspirin continued throughout
Low dose aspirin continued throughout FIGURE 2. Proposed bridging protocols for high-risk patients on dual antiplatelet therapy referred to cardiac or noncardiac surgery. (a) Bridging strategy with small-molecule glycoprotein IIb/IIIa inhibitors. After discontinuation of the P2Y 12 inhibitor (7 days before surgery for prasugrel, 5 days before surgery for clopidogrel or ticagrelor), bridging with tirofiban or eptifibatide should be initiated approximately 72 h before surgery and continued up to 4-6 h from surgery. In the absence of specific dose-finding studies, the dosing regimen (0.1 mcg/kg/min for tirofiban, 2.0 mcg/kg/min for eptifibatide) should be that recommended according to the package insert of each molecule. A loading dose is not warranted, given that bridging does not occur in an acute setting requiring immediate effects. (b) Bridging strategy with cangrelor (cangrelor is an investigational product still not approved for clinical use). Cangrelor should be used at the dose of 0.75 mg/kg/min without a loading bolus. No renal adjustment is needed, as renal function does not affect cangrelor clearance. Treatment should be initiated within 72 h from P2Y 12 inhibitor discontinuation and may be extended up to 7 days. Discontinuation of cangrelor infusion can occur 1-6 h before surgery. After noncardiac surgery, clopidogrel should be resumed with a loading dose as soon as oral administration is possible. Prasugrel and ticagrelor administration should be discouraged in the early period after surgery, given their increased potential for bleeding complications. If oral administration of clopidogrel is not possible, postsurgery bridging with an intravenous agent should be considered. After coronary artery bypass graft surgery, initiation of P2Y 12 -inhibiting therapy is at the discretion of the treating physician based on clinical characteristics. Low-dose aspirin (<100 mg/day) should be administered continuously throughout the perioperative period, unless contraindicated. Reproduced with permission [37 & ]. ].
low-molecular-weight heparin does not stimulate platelets, it does not have platelet inhibitory effects, which are pivotal for bridging, and perioperative use of these relatively long-acting agents can increase bleeding risk [37 & ,79] . The ideal bridging agent should be able to achieve levels of platelet inhibition similar to that of the oral P2Y 12 receptor inhibitors, but with a rapid onset and offset of antiplatelet effect. To date, the only intravenous approved agents with prompt and potent platelet inhibitory effect and a relatively short offset of action are the small-molecule glycoprotein IIb/IIIa inhibitors (GPIs) tirofiban and eptifibatide. Bridging strategies with perioperative infusion of tirofiban and eptifibatide have been shown to be feasible and reasonably safe in small-size observational studies, even though randomized trials are lacking [5, [80] [81] [82] [83] . A meta-analysis pooling together the results of eight studies (280 patients) on bridging with GPIs in patients with coronary stents undergoing surgery showed that this strategy does not completely eliminate the risk of perioperative stent thrombosis and may carry an increased risk of bleeding [84 && ].
Cangrelor is a potent intravenous ATP analog that directly and reversibly binds to the P2Y 12 receptor without being metabolized. It has a very fast onset and offset of action, with platelet reactivity returning to baseline levels within 30-60 min from infusion discontinuation [85] . Compared with GPIs, cangrelor has more desirable pharmacologic properties for bridging ( Table 2 ). This hypothesis was tested in patients treated with DAPT and requiring CABG in the Bridging Antiplatelet Therapy With Cangrelor In Patients Undergoing Cardiac Surgery (BRIDGE) trial [86] . After a dose-findings phase, cangrelor (at a dose of 0.75 mg/kg/min) was shown to achieve high and stable levels of platelet inhibition during up to 7 days of infusions, with a very rapid offset of action after discontinuation prior to surgery. Further, this effect was achieved without an increased risk of major bleeding or side-effects before or during CABG. Although this strategy may be valid also in noncardiac surgery, cangrelor has yet to be tested in this setting. Even if cangrelor is not currently approved for clinical use and is being evaluated by regulating agencies worldwide, bridging strategies with cangrelor or small-molecule GPIs are suggested and schematized in Fig. 2 [37 & ]. However, it should be noted that the main limitation of parenteral antithrombotic therapies as bridging to surgery is the need for several days of hospitalization, with the consequent increase in costs.
CONCLUSION
Surgical procedures are characterized by an increased risk of ischemic and bleeding events, and management of antiplatelet therapy in the perioperative period is critical because it may strongly influence outcomes. Elective surgery must be postponed at least 4 weeks after BMS implantation and 6-12 months after new-generation DES. While aspirin should generally be continued throughout the perioperative period, especially in CABG surgery, the decision process for temporary DAPT interruption should be on the basis of a careful risk stratification balancing specific hemorrhagic and thrombotic risks. The use of bridging strategies may be useful to improve outcomes in high-risk patients, who should ideally be referred to hospitals where 24/7 emergency PCI is available. Indeed, there is a lack of knowledge on the perioperative management of antiplatelet therapy, which highlights the need for well-designed randomized clinical trials. In the absence of these, high-quality multicenter registries based on the use of a standardized approach for the management of antiplatelet therapy, such as the ongoing Surgery After Stenting registry (NCT01997242), will provide useful information to define future strategies.
